---
title: 'Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic
  Factors'
date: '2024-11-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39545524/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241116183752&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Trimodal therapy comprising surgical resection, pRT and
  TMZ-based chemotherapy appears to have the most beneficial effect on survival in
  GSM patients. Smaller tumor size, younger age and methylated MGMT promoters are
  associated with improved survival. To our knowledge, this is the largest multi-institutional
  cohort study investigating outcomes and prognostic factors for ...'
disable_comments: true
---
CONCLUSIONS: Trimodal therapy comprising surgical resection, pRT and TMZ-based chemotherapy appears to have the most beneficial effect on survival in GSM patients. Smaller tumor size, younger age and methylated MGMT promoters are associated with improved survival. To our knowledge, this is the largest multi-institutional cohort study investigating outcomes and prognostic factors for ...